UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 361

Sortiert nach

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Lung cancer (Amsterdam, Netherlands), 2020-10, Vol.148, p.1-11

2020

Link zum Volltext

Verfügbarkeit prüfen

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Lung cancer (Amsterdam, Netherlands), 2018-01, Vol.115, p.21-27

2018

Link zum Volltext

Verfügbarkeit prüfen

Grading the neuroendocrine tumors of the lung: an evidence-based proposal

Endocrine-related cancer, 2014-02, Vol.21 (1), p.1-16

2014

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?

Annals of oncology, 2020-11, Vol.31 (11), p.1581-1582

2020

Link zum Volltext

Verfügbarkeit prüfen

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib

Chemical science (Cambridge), 2018-03, Vol.9 (10), p.2740-2749

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting the MET gene for the treatment of non-small-cell lung cancer

Critical reviews in oncology/hematology, 2014-02, Vol.89 (2), p.284-299

2014

Link zum Volltext

Verfügbarkeit prüfen

Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient

Annals of oncology, 2017-06, Vol.28 (6), p.1405-1406

2017

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

JNCI : Journal of the National Cancer Institute, 2007-06, Vol.99 (11), p.847-857

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

British journal of cancer, 2013-08, Vol.109 (3), p.552-558

2013

Link zum Volltext

Verfügbarkeit prüfen

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies

British journal of cancer, 2024-01, Vol.130 (1), p.135-142

2024

Link zum Volltext

Verfügbarkeit prüfen

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations

Critical reviews in oncology/hematology, 2016-08, Vol.104, p.9-20

2016

Link zum Volltext

Verfügbarkeit prüfen

MET and ALK as targets for the treatment of NSCLC

Current pharmaceutical design, 2014-01, Vol.20 (24), p.3914

2014

Link zum Volltext

Verfügbarkeit prüfen

Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

Journal of thrombosis and haemostasis, 2016-01, Vol.14 (1), p.105-113

2016

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2024-01, Vol.187, p.107438-107438, Article 107438

2024

Link zum Volltext

Verfügbarkeit prüfen

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

Lung cancer (Amsterdam, Netherlands), 2011-02, Vol.71 (2), p.241-243

2011

Link zum Volltext

Verfügbarkeit prüfen

Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

Lung cancer (Amsterdam, Netherlands), 2012-03, Vol.75 (3), p.360-367

2012

Link zum Volltext

Verfügbarkeit prüfen

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

British journal of cancer, 2013-04, Vol.108 (8), p.1695-1703

2013

Link zum Volltext

Verfügbarkeit prüfen

Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer

Annals of oncology, 2015-05, Vol.26 (5), p.1035-1036

2015

Link zum Volltext

Verfügbarkeit prüfen

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial

Annals of oncology, 2019-04, Vol.30, p.ii67-ii68

2019

Link zum Volltext

Verfügbarkeit prüfen

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC

Annals of oncology, 2019-04, Vol.30, p.ii55-ii56

2019

Link zum Volltext

Verfügbarkeit prüfen

Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC

Annals of oncology, 2019-04, Vol.30, p.ii1-ii1

2019

Link zum Volltext

Verfügbarkeit prüfen

Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial

Annals of oncology, 2019-10, Vol.30, p.v609-v610

2019

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

Clinical & translational oncology, 2020-06, Vol.22 (6), p.844-851

2020

Link zum Volltext

Verfügbarkeit prüfen

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S57-S57

2016

Link zum Volltext

Verfügbarkeit prüfen

Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study

Annals of oncology, 2018-10, Vol.29, p.viii674-viii674

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 361

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(345)
Mit Volltextzugriff
(331)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Life Sciences & Biomedicine
(116)
Humans
(106)
Male
(66)
Female
(59)
Oncology
(48)
Aged
(45)
Middle Aged
(43)
Lung Neoplasms - Drug Therapy
(37)
Adult
(35)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(32)
Biological And Medical Sciences
(24)
Medical Sciences
(23)
Aged, 80 And Over
(22)
Lung Cancer
(20)
Pharmacology & Pharmacy
(19)
Infectious Diseases
(18)
Lung Neoplasms - Pathology
(18)
Treatment Outcome
(18)
Antineoplastic Agents - Therapeutic Use
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Grading the neuroendocrine tumors of the lung: an evidence-based proposal

Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib

Targeting the MET gene for the treatment of non-small-cell lung cancer

Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations

MET and ALK as targets for the treatment of NSCLC

Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC)

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC

Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC

Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC

Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study

Suchergebnisse filtern